Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing management team has acquired Ardena, a specialist contract development and manufacturing organization (CDMO) focused on early phase drug development, from Mentha Capital.
 
Ardena is a multi-service CDMO, assisting small-to-mid sized biopharma with services spanning the full development life cycle. The company offers a comprehensive “Make, Analyze, File” model from drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development. Headquartered in Belgium, the company operates across several sites in the Netherlands, Sweden and Latvia.
 
With a strong reputation for quality and a flexible service delivery model, Ardena caters to a highly diversified base of over 300 customers throughout Europe, the U.S., Japan and Korea.
 
With extensive sectoral expertise and network in the global biopharma industry, the GHO team will support management in accelerating Ardena’s plan to enable customers to take a molecule from ‘target to clinic’ with a single outsourced drug development service provider.
 
GHO plans to further strengthen Ardena’s broad service proposition through organic and inorganic opportunities, adding to both the company’s offering and international footprint.   The company is well-positioned to benefit from sector trends as an increasing number of biopharma companies outsource large parts of their early stage drug development work to highly specialized CDMOs.
 
“With their deep expertise in the Pharma sector, we are excited now to partner with GHO as we continue our international growth,” said Harry Christiaens, chief executive officer, Ardena. “Ardena and GHO are fully committed to the science-led approach that delivers valuable solutions for our biopharma customers globally.”